Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

s primarily due to increased employee expenses and increased costs associated with operating as a public company. The decrease for the nine month period in 2008 was due primarily to higher financing related costs incurred in 2007 attributable to OncoGenex Technologies' preparation for an initial public offering in the 2007 period, partly offset by higher employee expenses and increased costs associated with operating as a public company in the 2008 period.

Net income for the third quarter and nine months ended September 30, 2008, was $4.6 million and $0.8 million respectively, compared to net losses of $1.9 million and $6.3 million respectively in 2007. The net income recognized in both 2008 periods was primarily due to the impact of an extraordinary gain on the reverse takeover of Sonus and a reversal of tax expense associated with the change in capital structure of OncoGenex Technologies, both non-cash items.

The Company had $17.2 million in cash, cash equivalents and short-term investments as of September 30, 2008, compared with $5.1 million as of December 31, 2007. The Company has 5,513,643 shares outstanding as at November 7, 2008 of which 694,431 are subject to escrow provisions. OncoGenex continues to believe it has sufficient cash, cash equivalents and short-term investments to fund its currently planned operations through 2009, including:

- completion to final data of its ongoing Phase 2 clinical trials of

OGX-011;

- completion of its Phase 1 clinical trial of OGX-427;

- reaching an agreement with the U.S. Food and Drug Administration

(FDA) on the design of an additional Phase 3 registration trial of

OGX-011 in patients with hormone refractory prostate cancer via the

Special Protocol Assessment (SPA) process; and

- completion of pharmacology and formulation evaluations of CSP-9222.

"We have achieved important milestones in the third quarter of 2008 further
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... HILL, N.C. , May 29, 2015 /PRNewswire/ ... medical affairs function into roles involving clinical development, ... As its responsibilities have grown, Medical Affairs has ... function as a global group. And while its ... find it challenging to identify strong performance metrics ...
(Date:5/29/2015)... 29, 2015 In recent years, the biopharmaceutical ... Big Data that can generate valuable insights. Despite this, ... Big Data have caused the biopharmaceutical sector to embrace ... According to a recent study by benchmarking ... a Big Data team or function in place; however, ...
(Date:5/29/2015)... 2015 BerGenBio AS ("BerGenBio" or ... an abstract on the latest data on BGB324, the ... receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal ... in conjunction with the 2015 American Society of Clinical ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... Laboratory (NPL), in collaboration with Linkping University, Sweden, have ... be easily identified in ambient conditions using Electrostatic Force ... usually only applicable to the material that consists of ... synthesis of any number of layers is possible, the ...
... Applications International Corporation (SAIC) (NYSE: SAI ) ... chief executive officer of SAIC-Frederick, Inc., a wholly owned ... Dr. Larry Arthur, who has served as CEO since ... SAIC-Frederick provides operations and technical support to ...
... Benefiting from recent investments in production and enormous demand ... record quarter. The leading developer of topical biotechnology for hair ... over Q1 of 2010. It was the fastest growth since ... "Although Q1 delivered a stellar number — made ...
Cached Biology Technology:Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc. 2Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc. 3First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 2First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 3
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... high levels of genetic diversity and acquire mutations to ... a vaccine. David Nickle et al present here an ... diversity of HIV or other variable pathogens. , This ... the strains of the virus by describing the molecules ...
... a box glowing with fluorescent light, Stacie Grassano pulls out a ... plastic up to her face. Inside, a tree branch is speckled ... to Scott Costa. , Costa brings the branch close to his ... fungus success story." , For some, a fungus success story ...
... of eight hospitals in Peru has shown that opening ... of mechanically ventilated negative-pressure rooms and 18 times that ... The researchers, led by Rod Escombe from Imperial College ... rooms such as respiratory isolation rooms, TB wards, respiratory ...
Cached Biology News:Immunization rates hit record high in poor countries 2Immunization rates hit record high in poor countries 3
...
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
... Shakers combine high durability and capacity ... of use. The patented triple-counterbalanced heavy-duty ... to run at high speed with ... temperature range is delivered with tight ...
Biology Products: